Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial

BMC Cancer

Volumn 10, Issue 1, 2010, Pages

  Schwartzberg, Lee ^a   Burkes, Ronald ^b   Mirtsching, Barry ^c   Rearden, Timothy ^d   Silberstein, Peter ^e   Yee, Lorrin ^f   Inamoto, Amy ^g   Lillie, Tom ^g  

^a WEST CLINIC   (United States)

^b MOUNT SINAI HOSPITAL   (Canada)

^c Dermatology Treatment and Research Center   (United States)

^d Hematology Oncology Consultants Inc   (United States)

^e CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Pac International Engineering PLLC   (United States)

^g AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; ERYTHROPOIETIN;

ADULT; ANEMIA; ARTHRALGIA; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DEMOGRAPHY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HEART ARRHYTHMIA; HEART ATRIUM THROMBOSIS; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; IMMUNOPATHOLOGY; JUGULAR VEIN THROMBOSIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PHLEBITIS; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SUPERFICIAL THROMBOPHLEBITIS; SUPERIOR CAVA VEIN OBSTRUCTION; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; UPPER EXTREMITY DEEP VEIN THROMBOSIS; AGED; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DAILY LIFE ACTIVITY; DRUG ADMINISTRATION; MIDDLE AGED; NEOPLASM; QUALITY OF LIFE; TIME;

ACTIVITIES OF DAILY LIVING; AGED; ANEMIA; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; FEMALE; HEMATINICS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; QUALITY OF LIFE; TIME FACTORS; TREATMENT OUTCOME;

EID: 77958144905     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-581     Document Type: Article

References (20)

1. Groopman JE, Itri LM: Chemotherapy-induced anemia in adults: incidence and treatment. J Nat Cancer Inst 1999, 91(19):1616-1634
2. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH: Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001, 19(11):2875-2882
3. Hedenus M, Adriansson M, San Miguel J, Kramer MH, Schipperus MR, Juvonen E, Taylor K, Belch A, Altes A, Martinelli G, et al: Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003, 122(3):394-403
4. Vadhan-Raj S, Mirtsching B, Charu V, Terry D, Rossi G, Tomita D, McGuire WP: Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks. J Supp Oncol 2003, 1(2):131-138
5. Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gateley J, Tomita D, Colowick AB, et al: Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Nat Cancer Inst 2002, 94(16):1211-1220
6. Aranesp® (Darbepoetin alfa) Package Insert. Amgen Inc., Thousand Oaks, CA; 2010
7. Herrington JD, Davidson SL, Tomita DK, Green L, Smith RE, Boccia RV: Utilization of darbepoetin alfa and epoetin alfa for chemotherapyinduced anemia. Am J Health-System Pharm 2005, 62(1):54-62
8. Schwartzberg L, Shiffman R, Tomita D, Stolshek B, Rossi G, Adamson R: A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Clin Ther 2003, 25(11):2781-2796
9. Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE: Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 2002, 24(6):547-561
10. Glaspy J, Vadhan-Raj S, Patel R, Bosserman L, Hu E, Lloyd RE, Boccia RV, Tomita D, Rossi G: Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapyinduced anemia: the 20030125 Study Group Trial. J Clin Oncol 2006, 24(15):2290-2297
11. Canon JL, Vansteenkiste J, Bodoky G, Mateos MV, Bastit L, Ferreira I, Rossi G, Amado RG: Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Nat Cancer Inst 2006, 98(4):273-284
12. Boccia R, Malik IA, Raja V, Kahanic S, Liu R, Lillie T, Tomita D, Clowney B, Silberstein P: Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia. Oncologist 2006, 11(4):409-417
13. Kotasek D, Steger G, Faught W, Underhill C, Poulsen E, Colowick AB, Rossi G, Mackey J, Aranesp 980291 Study Group: Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebocontrolled, randomised study. Eur J Cancer 2003, 39(14):2026-2034
14. Amgen Announces Interim Results of Aranesp® "PREPARE" Study in Breast Cancer Patients. [http://www.immunex.com/media/media_pr_detail. jsp?year=2007&releaseID=1083091]
15. Smith RE Jr, Aapro MS, Ludwig H, Pinter T, Smakal M, Ciuleanu TE, Chen L, Lillie T, Glaspy JA: Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebocontrolled study. J Clin Oncol 2008, 26(7):1040-1050
16. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003, 362(9392):1255-1260
17. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, et al: Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005, 23(25):5960-5972
18. Thomas G, Ali S, Hoebers FJ, Darcy KM, Rodgers WH, Patel M, Abulafia O, Lucci JA, Begg AC: Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 2008, 108(2):317-325
19. Overgaard J, HoffC, Sand Hansen H, Specht L, Overgaard M, Grau C, Andersen E, Johansen J, Andersen L, Evensen J: Randomized study of the importance of Novel Erythropoiesis Stimulating Protein (Aranesp®) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC)-the Danish Head and Neck Cancer Group (DAHANCA 10). Eur J Cancer Suppl 2007, 5(6):7, (Abstract 6LB)
20. Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, Szechtman B, Roa W, Mulroy L, Rudinskas L, et al: Randomized, double-blind, placebocontrolled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007, 25(9):1027-1032